Jesper Jorgensen | New Product Planning Lead
UCB

Day 2 - Wednesday 29 October @ 09:45

Keynote panel: New treatments on the block – 2025’s rare disease pipeline

-What are the most exciting new drugs on RDs therapies and gene therapies on the horizon?

-How are policies adapting to meet the increase of new approvals?

-How do we keep rare disease drug development sustainable? Supporting a better economic, policy and regulatory framework to incentivise companies

Moderator: Paolo Morgese, Vice President, Public Affairs, Europe, Alliance for Regenerative Medicine

P.J. Brooks, Deputy Director, Division of Rare Diseases Research Innovation, Chair of IRDiRC Companies Constituent Committee (CCC), NIH/NCATS

Violeta Stoyanova-Beninska, Senior Scientific Specialist at Human Division EMA, Chair of Regulatory Science Committee, IRDiRC, former Chair of COMP at EMA, EMA

×

Violeta Stoyanova-Beninska / Keynote panel: New treatments on the block – 2025’s rare disease pipeline

Violeta Stoyanova-Beninska, Senior Scientific Specialist at Human Division EMA, Chair of Regulatory Science Committee, IRDiRC, former Chair of COMP at EMA,
EMA

Dr. Violeta Stoyanova-Beninska is a medical doctor with a PhD in molecular genetics and a Master of public health degree. As a regulator and scientist Violeta has dedicated her career to clinical work, research in genetics and regulation of medicines and in particular to therapies for rare and...

CloseMore

Jennifer Schranz, SVP, Global Head Rare Diseases, Ipsen

Jesper Jorgensen, New Product Planning Lead, UCB

×

Jesper Jorgensen / Keynote panel: New treatments on the block – 2025’s rare disease pipeline

Jesper Jorgensen, New Product Planning Lead,
UCB

UCB New Product Planning Lead for early gene therapy and neurodegeneration portfolio. Past experience in Access/Pricing roles (10 years) from the Cell and Gene Therapy Catapult and ICON Plc. consulting. Author of 10 peer-reviewed articles on access-reated topics in the cell and gene therapy space. 

Close